<p>Type 2 Diabetes (T2D) is the most prevalent metabolic disorder globally, characterized by chronic hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. It primarily arises from disruptions in insulin action and secretion, often accompanied by impaired pancreatic function. T2D is closely associated with serious microvascular complications such as nephropathy, neuropathy, and retinopathy, as well as macrovascular conditions including hypertension, atherosclerosis, and stroke. Both genetic predisposition and environmental influences contribute to its onset and progression. Although genome-wide association studies have identified numerous loci associated with type 2 diabetes, these common genetic variants collectively explain only ~ 10–15% of the estimated heritability of the disease, indicating that the majority of genetic risk remains unexplained by known variants. Altered DNA methylation patterns have been identified in key tissues involved in T2D, including adipose tissue, liver, skeletal muscle, and pancreatic islets. These epigenetic alterations modulate the expression of genes governing insulin signaling and glucose metabolism. Notably, appropriate DNA methylation is essential for the development and functional integrity of pancreatic β-cells, and disruptions in these patterns can lead to impaired insulin synthesis and secretion. These modifications are dynamic and can be influenced by age, lifestyle, family history, and disease state, thereby linking environmental factors to long-term metabolic outcomes. Emerging evidence highlights that epigenetic modifications particularly changes in DNA methylation patterns in genes such as TXNIP, PPARGC1A, and ABCG1 may serve as early biomarkers of metabolic dysfunction, detectable even before clinical symptoms arise. These epigenetic signatures hold potential for early disease prediction, risk assessment, and monitoring of therapeutic response. Furthermore, since epigenetic changes are dynamic and reversible, they represent attractive therapeutic targets. Agents such as DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors may help restore normal gene expression and improve insulin sensitivity. Additionally, lifestyle interventions including diet, exercise, and weight management can beneficially modulate epigenetic marks, offering a complementary approach to pharmacological therapies.</p>